StephenRobertMarderMD

Professor at UCLA Director, Section on Psychosis - UCLA Neuropsychiatric Institute and Hospital Director, Section on Psychosis - UCLA Semel Institute Professor and Director, Section on Psychosis UCLA Semel Institute of Neuroscience and Human Behavior, David Geffen School of Medicine at UCLA Director, MIRECC - VA Greater Los Angeles Healthcare System

Join to view full profile

Dr. Marder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Marder's full profile

Already have an account?

Office
300 UCLA Medical Plz Ste 2200
Los Angeles, CA 90095
Phone+1 310-825-9989

Fax+1 310-206-4446

Education & Training

University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Psychiatry, 1972 - 1975
Jacobs School of Medicine and Biomedical Sciences at the University at BuffaloClass of 1971

Certifications & Licensure

CA State Medical License 1972 - 2025
MD State Medical License 1976 - 1979
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Supported Employment and Skills Training in Conjunction With Pharmacotherapy in Schizophrenia Patients Start of enrollment: 2000 Jun 01
Completed
Phase 4
Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults Start of enrollment: 2011 Aug 01
Completed
Phase 2
Does Acute Oxytocin Administration Enhance Social Cognition in Individuals With Schizophrenia? Start of enrollment: 2011 Apr 01
Completed
Not Applicable
Pharmacological Approach to Improve the Outcome of Social Cognition Training Start of enrollment: 2012 Jan 01
Completed
Phase 1
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia Start of enrollment: 2013 Jun 01
Completed
Phase 1
A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia Start of enrollment: 2014 Feb 01
Withdrawn
Phase 2
Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia Start of enrollment: 2014 Jul 01
Completed
Phase 1, Phase 2
Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia Start of enrollment: 2018 Dec 01
Active, not recruiting
Phase 2, Phase 3
A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia Start of enrollment: 2020 Jan 13
Terminated
Phase 2
Roles: Contact
Target Engagement and Response to Oxytocin Start of enrollment: 2018 Jan 04
Active, not recruiting
Phase 4
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

5 citations
Efficacy of KarXT on negative symptoms in acute schizophrenia: A post hoc analysis of pooled data from 3 trials.
William P Horan, Steven D Targum, Amy Claxton, Inder Kaul, Samantha E Yohn
Schizophrenia Research. 2024-12-01
1 citations
Does relapse cause illness progression in first-episode psychosis? A review.
Kevin P Kennedy, Michael F Zito, Stephen R Marder
Schizophrenia Research. 2024-09-01
1 citations
Effects of PDE10A inhibitor MK-8189 in people with an acute episode of schizophrenia: A randomized proof-of-concept clinical trial.
Yuki Mukai, Robert Lupinacci, Stephen Marder, Linda Snow-Adami, Tiffini Voss
Schizophrenia Research. 2024-08-01

Journal Articles

Reliability and Validity of the Self-Report Version of the Apathy Evaluation Scale in First-Episode Psychosis: Concordance with the Clinical Version at Baseline and 12...
Stephen Marder, MD, Psychiatry Research

Authored Content

A Dose-Finding Study of Oxytocin Using Neurophysiological Measures of Social ProcessingJuly 2018

Press Mentions

Amyloid Fibers Reveal Themselves with near‐InfraredSeptember 3rd, 2020
FDA Approves Daily Asenapine PatchNovember 7th, 2019
Major Announcement: Schizophrenia Bulletin OpenSeptember 18th, 2019
Join now to see all

Grant Support

Opportunities For Innovative Drug Development For SchizophreniaNational Institute Of Mental Health2009–2010
Treatment Units For Research On Neurocognition &Schizophrenia (TURNS)National Institute Of Mental Health2007
Relapse Prevention: Long-Acting Atypical AntipsychoticsNational Institute Of Mental Health2006
Management For Risk Of Relapse In SchizophreniaNational Institute Of Mental Health1993–2004
Treatment Of Negative Symptoms &Cognitive ImpairmentsNational Institute Of Mental Health2000–2003
Core--Psychopharmacology LaboratoryNational Institute Of Mental Health1996–2000
New Antipsychotics--Clinical Trials And FollowupNational Institute Of Mental Health1995–1997
Predicting Optimal Neuroleptic Therapy For SchizophreniaNational Institute Of Mental Health1995
New Antipsychotics--Use In New PopulationsNational Institute Of Mental Health1995
Management Of Risk For Relapse In SchizophreniaNational Institute Of Mental Health1995
Core--Psychopharmacology LaboratoryNational Institute Of Mental Health1995
Predicting Optimal Neuroleptic Therapy For Schizophrenic OutpatientsNational Institute Of Mental Health1985–1995
Clozapine--Treatment Response And DisabilityNational Institute Of Mental Health1992–1994
Management Of Risk For Relapse In SchizophreniaNational Institute Of Mental Health1986–1990